ArticleFood chemistry: X2025
Characterization and antidiabetic activity of cinnamon essential oil emulsion encapsulated by complex coacervation between gelatin and soluble fraction of tragacanth gum.
Article in Food chemistry: X, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Improving Sexual Dysfunction with Cinnamon Leaf Extract and Nanoemulsion by Using a Rat Model.Pharmaceuticals (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Complex coacervates of gelatin (GE) and the soluble fraction of tragacanth gum (STG) at ratios of 1:2, 1:1, and 2:1 were developed to encapsulate cinnamon essential oil (CEO). These coacervates were assessed for particle yield, encapsulation efficiency, and encapsulation yield. GE2:STG1/CEO50 %, GE1:STG1/CEO25 %, and GE1:STG1/CEO50 % showed the highest encapsulation efficiency, with the latter also exhibiting the highest encapsulation yield, identifying it as the optimal formulation. FTIR confirmed intermolecular interactions, while microscopy showed rough surfaces without cracks. Thermogravimetric analysis revealed improved CEO thermal stability. Toxicity assay results showed that encapsulation reduced the cytotoxicity of CEO. CEO release was higher under simulated intestinal (42.63 %) than gastric (34.91 %) conditions. The encapsulated CEO inhibited α-amylase and α-glucosidase activities dose-dependently. These findings suggest that GE-STG coacervates provide an effective and biocompatible delivery system for CEO, offering improved stability, controlled intestinal release, and enhanced antidiabetic potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.